| scholarly article | Q13442814 |
| P50 | author | Youngkeun Ahn | Q87419336 |
| P2093 | author name string | Myung Ho Jeong | |
| Jae Yeong Cho | |||
| P2860 | cites work | Mussel-inspired surface chemistry for multifunctional coatings | Q22242278 |
| Alpha-lipoic acid as a biological antioxidant | Q27863439 | ||
| Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury | Q28378543 | ||
| Probucol | Q34107317 | ||
| Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize | Q34207990 | ||
| Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty | Q34336722 | ||
| Heparin-protein interactions | Q35030190 | ||
| Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model | Q35048369 | ||
| Drug-eluting stents in vascular intervention | Q35053441 | ||
| Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease | Q35088534 | ||
| Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model | Q35343351 | ||
| The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease | Q35936923 | ||
| Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine | Q36358107 | ||
| Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis | Q36942534 | ||
| Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model | Q37221177 | ||
| Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". | Q37358508 | ||
| A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies | Q37638598 | ||
| Drug-eluting stent coatings | Q37668357 | ||
| Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial | Q38465621 | ||
| Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). | Q38467326 | ||
| Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). | Q38476348 | ||
| Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression | Q38512994 | ||
| Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model | Q39287146 | ||
| Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy | Q39475393 | ||
| Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia | Q39577142 | ||
| Biodegradable nano-polymeric system for efficient Akt1 siRNA delivery | Q39720081 | ||
| Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells | Q39842082 | ||
| Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease | Q41017012 | ||
| 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. | Q41123265 | ||
| Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. | Q41191808 | ||
| Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery | Q42167198 | ||
| Carvedilol Inhibits Vascular Smooth Muscle Cell Proliferation | Q42482770 | ||
| Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Sten | Q42851160 | ||
| Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent f | Q42872756 | ||
| Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease | Q43072961 | ||
| Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial | Q43198903 | ||
| Effect of alpha lipoic acid in a porcine in-stent restenosis model. | Q43234458 | ||
| Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. | Q43824509 | ||
| Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study | Q43864405 | ||
| The role of surface functional groups in calcium phosphate nucleation on titanium foil: a self-assembled monolayer technique | Q44052975 | ||
| Effects of AGI-1067 and probucol after percutaneous coronary interventions. | Q44302074 | ||
| Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial | Q44479094 | ||
| Novel abciximab-Kruppel-like factor 4-plasmid dual-delivery titanium dioxide-coated coronary stent | Q44515372 | ||
| Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization | Q44612131 | ||
| Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction | Q44850788 | ||
| The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway | Q45887270 | ||
| Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. | Q45968266 | ||
| What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation? | Q46778422 | ||
| Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial | Q46824045 | ||
| Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators | Q48661347 | ||
| Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents | Q50176817 | ||
| Thromboresistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface | Q50250895 | ||
| Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis. | Q51067686 | ||
| The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. | Q51253557 | ||
| Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. | Q51386024 | ||
| Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. | Q51438968 | ||
| Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. | Q53362662 | ||
| Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease. | Q53481533 | ||
| Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients | Q54264575 | ||
| The efficacy and safety of drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR) | Q57224324 | ||
| Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization | Q57694960 | ||
| Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial | Q61651385 | ||
| Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty | Q67278737 | ||
| Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty | Q67299486 | ||
| Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils | Q68499801 | ||
| Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system | Q70993085 | ||
| Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty | Q71244186 | ||
| Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study | Q71401325 | ||
| Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure | Q72726571 | ||
| Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis | Q72852264 | ||
| Preventive effects of the heparin-coated stent on restenosis in the porcine model | Q73091870 | ||
| Surface characterization and in vitro blood compatibility of poly(ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge | Q73347675 | ||
| Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study | Q73368849 | ||
| Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group | Q73552611 | ||
| Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells | Q73836408 | ||
| Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins | Q77296586 | ||
| Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group | Q77781907 | ||
| Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty | Q77958677 | ||
| Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy | Q78239362 | ||
| The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system | Q83235774 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P304 | page(s) | 645-654 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Korean circulation journal | Q26842331 |
| P1476 | title | A bumpy and winding but right path to domestic drug-eluting coronary stents | |
| P478 | volume | 43 |
| Q42262004 | Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction | cites work | P2860 |
Search more.